J Korean Soc Endocrinol.  2005 Feb;20(1):21-28. 10.3803/jkes.2005.20.1.21.

The Efficacy of MIBG Scan as a Diagnostic and Docalization Test for Pheochromocytoma

• Park CK
• Kim KW
• Kim DH
• Kim JH
• Kang JG
• Kim SW
• Cho YM
• Park DJ
• Shin CS
• Park KS
• Cho BY
• Lee HK
• Kim SY

• KMID: 2100450
• DOI: http://doi.org/10.3803/jkes.2005.20.1.21

Abstract

BACKGROUND: Computed tomography(CT) is currently considered as the initial imaging procedure of choice for the localization of pheochromocytomas in most of the cases. 131I-or 123I-Metaiodobenzylguanidine scintigraphy(MIBG scan) was proven to be a highly specific tool for the detection of adrenal and extra-adrenal pheochromocytomas, but was less sensitive than CT. The present study is aimed to evaluate the usefulness of a MIBG scan in diagnosis and localization of pheochromocytoma when compared to CT.
METHODS
We retrospectively evaluated 27 patients who underwent a MIBG scan for a pheochromocytoma at the Seoul National University Hospital from the year 2000 and 2002. According to the pathological and clinical findings, in 16 the patients pheochromocytoma was confirmed to be positive and the rest 11 of the patients were excluded from the study.
RESULTS
Pheochromocytomas was identified in 16 patients. Eleven of them were localized in adrenal gland and 5 were extra-adrenal lesions. The sensitivity to MIBG scan in adrenal lesions and extra-adrenal lesions, was 72%(8/11) and 40%(2/5) respectively. In our study, the overall sensitivity to MIBG scan was 62%(10/16), and overall specificity was 90.9%(10/11). By CT four were identified to have equivocal biochemical abnormalities, but were definite and extraadrenal tumors by MIBG scan showed abnormal uptakes in two of them.
CONCLUSION
The MIBG scan was especially useful in 2 of the 27 patients but we had no experienced about the additional benefits of a MIBG scan in the other 25 cases. Our results reveal that a MIBG scan should be performed carefully for the diagnosis and localization of a pheochromocytoma, while considering cost and time of operation.

MeSH Terms

3-Iodobenzylguanidine*
Adrenal Glands
Diagnosis
Humans
Pheochromocytoma*
Retrospective Studies
Sensitivity and Specificity
Seoul
3-Iodobenzylguanidine

Figure

• 

  Fig. 1 Flow diagram of diagnosis of pheochromocytoma

Reference

1. Manger WM, Gifford RW Jr. Clinical and Experimental Pheochromocytoma. 1996. Cambridge, MA: Blackwell Science.

2. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000. 85:637–644.

3. Chatal JF. Can we agree on the best image procedure for the localization of pheochromocytoma? J Nucl Med. 1993. 34:180–181.

4. Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991. 40:544–556.

5. Bravo EL, Tagle R. Pheochromocytoma: state-of art and future prospects. Endocr Rev. 2003. 24:539–553.

6. Pacak K, Linehan WM, Eisenholfer G, Walther MM, Goldstein DS. Recent advances in genetic, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001. 134:315–329.

7. Lasen PR, Kronenberg HM, Melmed S, Polondky KS. Williams Textbook of Endocrinology. 2003. 10th ed. Philadephia, Saunders: 552–562.

8. Bloom DA, Fonkalsrud EW. Surgical management of pheochromocytoma in children. J Pediatr Surg. 1974. 9:179–184.

9. Whalen RK, Althausen AF, Daniels GH. Extraadrenal pheochromocytomas. J Urol. 1992. 147:1–10.

10. Orchard T, Grant CS, van Heerden JA, Weaver A. Pheochromocytoma: Continuing evolution of surgical therapy. Surgery. 1993. 114:1153–1159.

11. Chatal JF, Charbonnel B. Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab. 1985. 61:769–772.

12. Koizumi M, Endo K, Sakahara H, et al. Computed tomography and 131I-MIBG scintigraphy in the diagnosis of pheochromocytoma. Acta Radiol Diagn (Stockh). 1986. 27:305–309.

13. Gough IR, Thompson NW, Shapiro B, Sisson JC. Limitations of 131 I-MIBG scitigraphy in locating pheochromocytomas. Surgery. 1985. 98:115–119.

14. Thompson NW, Allo MD, Shapiro B, Sisson JC, Beierwaltes W. Extra-adrenal and metastatic pheochromocytoma: The role of 131 I Meta-Iodobenzylguanidine (131 I MIBG) in localization and management. World J Surg. 1984. 8:605–611.

15. Campeau RJ, Garcia OM, Correa OA, Rege AB. Pheochromocytoma: diagnosis by scintigraphy using iodine 131 metaiodobenzylguanidine. South Med J. 1991. 84:1221–1230.

16. Velchik MG, Alavi A, Kressel HY, Engelman K. Localization of pheochromocytoma: MIGB, CT, and MRI correlation. J Nucl Med. 1989. 30:328–336.

17. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ. [¹²³I] Metaiodobenzylguanidine and [¹¹¹In] Octreotide Uptake in Benign and Malignant Pheochromocytomas. J Clin Endocrinol Metab. 2001. 86:685–693.

18. Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, Britton KE, Besser GM. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med. 1987. 28:973–978.

19. Jalil ND, Pattou FN, Combemale F, Chapuis Y, Henry JF, Peix JL, Proye CA. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Association of Surgery (AFC), and The French Association of Endocrine Surgeons (AFCE). Eur J Surg. 1998. 164:23–28.

20. Ackery DM, Tippett P, Condon B. New approach to the localization of pheochromocytoma; imaging with 131-I MIBG. Br Med J. 1984. 288:1587–1591.

21. Baulieu JL, Guilloteau C, Canbon C. MIBG scintigraphy: one year experience (Abstract). J Nuct Med. 1984. 25:III.

22. Brown ML, Sheps SG, Sizemore G. MIGB in the evaluation of suspected pheochromocytoma. Mayo Clinic experience (Abstract). J Nucl Med. 1984. 25:III.

23. Fisher M, Vetter W, Winterberg B. Scintigraphic localization of pheochromocytoma. Clin Endocrinol. 1984. 20:17–22.

24. Shapiro B, Copp JE, Sisson JC. Iodine 131 metaiodobenzyIguanidine for the location of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985. 26:576–585.

25. Francis IR, Glazer GM, Shapiro B, Sisson JC, Gross BH. Complementary roles of CT and ¹³¹I-MIBG scintigraphy in diagnosing pheochromocytoma. AJR Am J Roentgenol. 1983. 141:719–725.

26. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985. 26:576–585.

27. Chatal JF, Charbonnel B. Comparison of iodobe nzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab. 1985. 61:769–772.

28. Swensen SJ, Brown ML, Sheps SG, Sizemore GW, Gharib H, Grant CS, van Heerden JA. Use of ¹³¹I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma. Mayo Clin Proc. 1985. 60:299–304.

29. Thompson NW, Allo MD, Shapiro B, Sisson JC, Beierwaltes W. Extra-adrenal and metastatic pheochromocytoma: the role of 131I meta-iodobenzylguanidine (¹³¹I MIBG) in localization and management. World J Surg. 1984. 8:605–611.